Overview

Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)

Status:
Completed
Trial end date:
2021-11-02
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ultragenyx Pharmaceutical Inc